Viewing nowUnivaltan Tablet 80 mg (Valsartan)
Valsartan 80mg
Tablet · Prescription medication
Hwanin Pharmaceutical Co., Ltd.

MFDS item code 201001707 · Notified 2010.02.26 · Insurance code 657202170
Treatment of essential hypertension and heart failure; reduction of the risk of death after myocardial infarction
This medication is used to lower blood pressure in patients with essential hypertension and to reduce the strain on the heart. It also helps alleviate symptoms and improve heart function in heart failure patients who do not respond to ACE inhibitors. It is effective in reducing the risk of death in patients with reduced left ventricular function after myocardial infarction. Based on these effects, this medication is effective for blood pressure management, treatment of heart failure, and post-myocardial infarction therapy.
(Tablets) * 40, 80, 160 mg 1. Essential hypertension Take with water during or between meals. It is recommended to take the medicine at the same time each day, if possible (e.g., in the morning). 1) Adults: Regardless of sex or race, oral administration of valsartan 80 mg once daily is recommended. The blood pressure-lowering effect appears gradually within 2 weeks and reaches its maximum effect after 4 weeks. In patients whose blood pressure is not adequately controlled, the dose may be increased to 160 mg once daily or a diuretic may be coadministered. If further blood pressure reduction is needed, the dose may be increased to a maximum of 320 mg daily. 2) Older adults (75 years or older): Start treatment with 40 mg of this medicine once daily. 3) Patients with renal impairment: (1) Creatinine clearance 20 ∼ 50 mL/min: No dose adjustment is required. (2) Creatinine clearance 10 ∼ 20 mL/min: Start treatment with 40 mg of this medicine once daily. (3) Creatinine clearance below 10 mL/min and patients on dialysis: Do not administer this medicine. 4) Patients with intravascular volume depletion: In patients with intravascular volume depletion (e.g., patients taking high doses of diuretics whose dose cannot be reduced), start treatment with 40 mg of this medicine once daily. 5) Patients with hepatic impairment: In patients with mild or moderate hepatic impairment, start treatment with 40 mg of this medicine once daily, and do not exceed 80 mg daily. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis. 2. Heart failure Adults: The recommended starting dose is 40 mg of this medicine orally twice daily. The dose may be increased to 80 mg or 160 mg per dose. When coadministering a diuretic, consider reducing the diuretic dose. The maximum daily dose is 320 mg, administered in divided doses. Triple combination therapy with this medicine, an ACE inhibitor, and a beta-blocker is not recommended. 3. Reduction of the risk of death after myocardial infarction Adults: Treatment may be initiated within 12 hours of the onset of myocardial infarction. The recommended starting dose is 20 mg of this medicine twice daily; thereafter, over several weeks, the dose is increased according to the patient's tolerability to 40 mg, 80 mg, and 160 mg per dose, administered twice daily. Consider dose reduction if symptoms of hypotension or renal failure occur. This medicine may also be administered to patients receiving other treatments after myocardial infarction (e.g., thrombolytic agents, acetylsalicylic acid, beta-blockers, and statins). However, coadministration with an ACE inhibitor is not recommended. 4. Patients with renal impairment: No dose adjustment is required when creatinine clearance is 10 mL/min or higher. However, do not administer this medicine to patients with creatinine clearance below 10 mL/min or to patients on dialysis, as there is no experience with its use in these patients. 5. Patients with hepatic impairment: In patients with mild or moderate hepatic impairment, it is preferable that the daily dose of this medicine not exceed 80 mg. If administering 80 mg or more per day, consider whether the benefits of treatment outweigh the risks when increasing the dose. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis.
The safety and efficacy have not been established in children and adolescents under 18 years of age. The safety and efficacy have not been established in children and adolescents under 18 years of age.
This medication can cause serious harm to the fetus if taken during pregnancy, especially in the second and third trimesters, so if pregnancy is confirmed, use should be stopped immediately. Patients with allergic reactions to this medication or severely impaired liver or kidney function should not take it. Elderly patients, patients with hyperkalemia, and patients with impaired liver function should use this medication with special caution, as it can cause excessively low blood pressure, thus dosage should be increased slowly. Symptoms such as dizziness or hypotension may occur during the use of this medication, so caution is necessary when driving or operating machinery. Taking this medication with potassium-sparing diuretics or potassium supplements can dangerously increase potassium levels in the blood, so caution is warranted. There may be interactions with some painkillers, diuretics, and anticoagulants, so anyone taking other medications should consult with a doctor or pharmacist. Patients with heart failure or post-myocardial infarction should monitor kidney function and blood pressure regularly during treatment. Possible adverse reactions during use include headache, dizziness, fatigue, cough, etc. If severe edema, difficulty breathing, or swelling of the face or lips occurs, medical attention should be sought immediately. In case of overdose, severe hypotension or decreased consciousness may occur, requiring immediate emergency treatment. Safety has not been established in children or adolescents, and use is not recommended. This medication should be kept out of reach of children, and it is safer not to transfer it to other containers.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly closed container to prevent air and moisture from entering. To maintain the effectiveness of the medication, it is recommended to keep it in a cool place below 30 degrees Celsius.
Light red round film-coated tablet
100 tablets (10 tablets/PTP × 10)
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowValsartan 80mg
Tablet · Prescription medication
Hwanin Pharmaceutical Co., Ltd.

Valsartan 80mg
Tablet · Prescription medication
Novartis Korea Co., Ltd.

Valsartan 160mg
Tablet · Prescription medication
Novartis Korea Co., Ltd.

Valsartan 40mg
Tablet · Prescription medication
Samsung Novartis Co., Ltd.
Valsartan
Prescription medication
Korea Sandos Co., Ltd.
Valsartan
Prescription medication
Korea Sandos Co., Ltd.

Valsartan
Prescription medication
Korea Sandos Co., Ltd.

Valsartan 320mg
Tablet · Prescription medication
Novartis Korea Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.